Accendra Health (NYSE: ACH) completes high-participation debt exchange
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Accendra Health, Inc. reports the expiration and final results of its exchange offers for its 4.500% Senior Notes due 2029 and 6.625% Senior Notes due 2030. Eligible holders tendered approximately $478.3 million of 2029 Notes and $548.0 million of 2030 Notes, representing about 99.9% and 99.2% of the amounts outstanding at launch. After cancellation of exchanged notes, $338,000 of 2029 Notes and $4,170,000 of 2030 Notes remained outstanding. In connection with the exchanges and a new money issuance, the company issued $213.0 million of First Lien Notes and $698.1 million of Second Lien Notes for existing notes, plus $326.25 million of new money First Lien Notes, for a total of $539.25 million First Lien Notes.
Positive
- None.
Negative
- None.
Insights
Accendra nearly fully exchanges existing notes, issuing new first- and second-lien debt plus significant new money.
Accendra Health completed high-participation exchange offers for its 4.500% 2029 Notes and 6.625% 2030 Notes. Holders tendered about 99.9% of 2029 principal and 99.2% of 2030 principal, leaving only $338,000 and $4,170,000 of those series outstanding.
In return, the company issued $213.0 million of First Lien Notes and $698.1 million of Second Lien Notes for tendered debt, and raised $326.25 million of additional First Lien Notes for cash, totaling $539.25 million First Lien Notes. These instruments are governed by existing indentures and were offered only to eligible institutional and non‑U.S. holders.
This transaction significantly reshapes the company’s debt mix across first- and second-lien tranches while adding new money capital. Future company filings may describe how this structure interacts with ongoing operations and any related covenants.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
2029 Notes tendered: $478.3 million aggregate principal
2030 Notes tendered: $548.0 million aggregate principal
2029 Notes remaining: $338,000 aggregate principal
+5 more
8 metrics
2029 Notes tendered
$478.3 million aggregate principal
4.500% Senior Notes due 2029 tendered, about 99.9% of launch amount
2030 Notes tendered
$548.0 million aggregate principal
6.625% Senior Notes due 2030 tendered, about 99.2% of launch amount
2029 Notes remaining
$338,000 aggregate principal
4.500% Senior Notes due 2029 outstanding after cancellation
2030 Notes remaining
$4,170,000 aggregate principal
6.625% Senior Notes due 2030 outstanding after cancellation
First Lien Notes (exchange)
$213.0 million aggregate principal
Issued in connection with exchange of existing notes
Second Lien Notes (exchange)
$698.1 million aggregate principal
Issued in connection with exchange of existing notes
First Lien Notes new money
$326.25 million aggregate principal
First Lien Notes issued for cash in New Money Notes Issuance
Total First Lien Notes
$539.25 million aggregate principal
Sum of exchange and new money First Lien Notes
Key Terms
Exchange Offers, Consent Solicitations, First Lien Notes, Second Lien Notes, +2 more
6 terms
Exchange Offers financial
"announced the expiration and final results of the previously announced offers to exchange (the “Exchange Offers”)"
An exchange offer is a proposal by a company to swap its existing financial instruments, like bonds or debt, for new ones, often with different terms or maturity dates. For investors, it provides a chance to adjust their holdings, often aiming for better returns or more favorable conditions, while helping the company manage its finances more effectively.
Consent Solicitations financial
"offers to exchange (the “Exchange Offers”) and consent solicitations (the “Consent Solicitations”)"
A consent solicitation is a formal request sent to shareholders asking them to approve or waive specific corporate actions — such as contract changes, mergers, or amendments to governance rules — often by signing a written consent instead of voting at a meeting. For investors this matters because it can speed up major decisions and alter rights or payments without a public vote, so shareholders need to weigh potential benefits, risks and any pressure to agree, much like neighbors being asked to sign off on a change to a shared driveway.
First Lien Notes financial
"the Company issued or expects to issue a total of: (i) $213.0 million in aggregate principal amount of First Lien Notes"
First lien notes are debt securities backed by specific assets that give their holders the top legal claim on those assets if the borrower can’t pay—think of them like a primary mortgage on a property: whoever holds the first lien gets paid off first from the sale. They matter to investors because that priority reduces the risk of losing principal compared with unsecured or lower-priority debt, usually meaning more protection but typically a lower yield.
Second Lien Notes financial
"and (ii) $698.1 million in aggregate principal amount of Second Lien Notes, in exchange for the validly tendered"
Second lien notes are loans or bonds that are backed by a company’s assets but sit behind first-lien debt in the pecking order for repayment; think of them like a second mortgage on a house. They matter to investors because they typically pay higher interest to compensate for the greater risk of getting paid only after first-lien creditors in a default, so they balance higher return potential against lower recovery chances.
Offering Memorandum financial
"conditions set forth in the confidential offering memorandum and consent solicitation statement, dated May 22, 2026 (the “Offering Memorandum”)"
A written document that describes the details of a private securities sale, including the investment terms, company background, financial information and the risks involved. Investors use it like a product brochure or car manual to compare offerings and understand what they're buying, how the money will be used and what could go wrong, which helps inform their decision and provides disclosure for legal protection.
forward-looking statements regulatory
"This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995."
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
FAQ
What did Accendra Health (ACH) announce in this 8-K filing?
Accendra Health announced the expiration and final results of its exchange offers for 4.500% 2029 Notes and 6.625% 2030 Notes, reporting very high participation and the issuance of new first-lien and second-lien notes plus additional first-lien notes for cash.
How many Accendra Health 2029 and 2030 notes were tendered in the exchange offers?
Eligible holders tendered approximately $478.3 million of 4.500% Senior Notes due 2029 and $548.0 million of 6.625% Senior Notes due 2030, representing about 99.9% and 99.2% of the aggregate principal amounts outstanding at the launch of the exchange offers, respectively.
How much Accendra Health debt remains outstanding after the exchange offers?
After accepting and cancelling exchanged securities, $338,000 in aggregate principal amount of 4.500% Senior Notes due 2029 and $4,170,000 in aggregate principal amount of 6.625% Senior Notes due 2030 remained outstanding, indicating that only a small fraction of each original series is still in place.
What new first-lien and second-lien notes did Accendra Health issue?
Accendra Health issued $213.0 million of First Lien Notes and $698.1 million of Second Lien Notes in exchange for existing notes. It also issued $326.25 million of additional First Lien Notes for cash, resulting in a total of $539.25 million First Lien Notes outstanding from these transactions.
Were Accendra Health’s new notes registered with the SEC?
The company stated that the new notes offered in the exchange have not been registered under the Securities Act or state securities laws, and may only be offered or sold pursuant to applicable exemptions, including Rule 144A for qualified institutional buyers and Regulation S for certain non‑U.S. persons.
Who could participate in Accendra Health’s exchange offers and consent solicitations?
Participation was limited to Eligible Holders of the existing notes: investors reasonably believed to be qualified institutional buyers under Rule 144A, and certain non‑U.S. persons in transactions outside the United States under Regulation S, as described in the confidential offering memorandum.